ADMA Biologics Posts 22-Cent Q3 EPS
ADMA sits 55% above its 52-week low of $7.21 on elevated volume (4.2× avg).
Summary
ADMA reported third-quarter earnings per share of 22 cents, per Dow Jones Newswires, with Q3 net income of USD 49.884 million and revenue up 5% to $141.1 million. That follows Q2 2026 net income of $37.8 million on $124.4 million of revenue, when ASCENIV growth offset BIVIGAM weakness. The company also increased its adjusted earnings outlook. The company has been returning capital aggressively, including a $125M accelerated share repurchase launched in March as part of a $200M 2026 plan, and buybacks lower the share count, which lifts EPS independent of operating results.
At the time of this announcement, ADMA was trading at $11.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.21 to $20.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.